Electromed, Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy systems used to help patients with compromised pulmonary function clear mucus and breathe more easily. Its core product is the SmartVest® Airway Clearance System, sold mainly through a direct-to-patient and provider model that works with clinicians, manages insurance reimbursement, and delivers devices for home use, with additional sales into hospitals and selected international markets.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueHFCWO devices that help mobilize secretions and improve bronchial drainage.
Patient onboarding, training, insurance claims support, and direct fulfillment for home use.
Device sales for inpatient, post-surgical, ICU, and respiratory therapy settings.
Customers
Electromed sells primarily to patients with physician prescriptions, but the buying process is driven by pulmonologists, cystic fibrosis centers, neuromuscular clinics, and other clinicians who identify candidates for HFCWO therapy. Its end markets include bronchiectasis, cystic fibrosis, neuromuscular disorders, and post-surgical or ventilator-dependent patients, with reimbursement from Medicare, Medicaid, HMOs, and private insurers often determining adoption. The company also serves hospitals, rental companies, and a limited number of HME distributors, especially in the U.S. homecare market.
Patients with bronchiectasis, cystic fibrosis, COPD-related bronchiectasis, and chronic pulmonary conditions who use SmartVest at home because it is prescribed, reimbursable, and supported by direct delivery and training.
Patients with ALS, cerebral palsy, muscular dystrophies, and similar conditions who need airway clearance to manage retained secretions and reduce respiratory complications.
Specialists and clinic staff who identify eligible patients, prescribe therapy, and influence adoption through clinical confidence and referral patterns.
Hospitals, rental companies, and other institutions purchasing HFCWO systems for inpatient, post-surgical, ICU, or infection-related respiratory support.
Limited distribution partners that extend reach in the U.S. homecare market and support incremental sales volume.
Strategy
Electromed is focused on expanding its direct sales force, increasing awareness of HFCWO therapy, and growing share in adult pulmonology and bronchiectasis. It is also trying to improve the patient experience through product innovation, while preserving its direct-to-patient model that captures both manufacturer and distributor economics. Management is adding territories, strengthening provider education, and selectively using HME distributors as an alternate channel.
More territories and reps should increase referrals, approvals, and homecare conversions.
This is described as the largest and fastest-growing addressable segment.
Better usability and comfort can support conversion, retention, and clinician preference.
Geography
2025Electromed is primarily a U.S. business, and management says most revenue comes from domestic homecare sales through its physician-referral model. The company also sells in the U.S. hospital market and has select international country approvals, but international demand is still a smaller and less consistent part of the mix. Geography matters because reimbursement, clinician awareness, and sales-force coverage drive adoption, while international distributor demand appears more variable.
Risks
Electromed depends on physician referrals, insurance reimbursement, and continued clinical acceptance of HFCWO therapy, so any slowdown in approvals or coverage can directly affect demand. Its business also has long-cycle hospital sales, some exposure to distributor demand, and a concentrated focus on a narrow set of respiratory indications, which makes growth sensitive to market penetration and sales-force execution. As with many medtech companies, it also faces regulatory, reimbursement, and product-development risks, plus accounting judgment around revenue recognition and share-based compensation.
The SmartVest System often relies on Medicare, Medicaid, HMOs, and private payer approval for adoption.
Exposure: Homecare sales and patient conversion
The direct-to-patient model depends on pulmonologists and clinicians prescribing therapy and supporting referrals.
Exposure: Core domestic revenue engine
The company depends on FDA clearance and ongoing compliance for marketed devices.
Exposure: Product portfolio and future launches
Hospital revenue can fluctuate with capital budget allocations and long sales cycles.
Exposure: Hospital and acute-care segment
Limited HME and international distributor sales can be uneven and depend on partner performance.
Exposure: Homecare distributor and other revenue
Accounting
Judgemental itemsRevenue is recognized when performance obligations are satisfied, but payer adjustments and channel mix can change timing and net amounts.
Impact: Affects reported revenue by channel and quarterly comparability
Hospital capital revenue depends on budget timing and can swing materially between quarters.
Impact: Can distort near-term growth rates and margin trends
Option and performance award expense depends on Black-Scholes and Monte Carlo assumptions.
Impact: Affects SG&A and diluted earnings
Similar listed companies
Publicly listed companies with a comparable business focus.
electroCore, Inc.
ECOR · Electromedical & Electrotherapeutic Apparatus
Tactile Systems Technology, Inc
TCMD · Surgical & Medical Instruments & Apparatus
Tactile Systems Technology is a U.S.-based medical technology company that develops and sells home-based devices for chronic disease management.
Pulmonx Corp
LUNG · Surgical & Medical Instruments & Apparatus
Pulmonx Corp is a U.S.-based medical device company focused on minimally invasive treatments for severe emphysema and other advanced chronic obstructive pulmonary disease (COPD) patients.
IR-Med, Inc.
Electromedical & Electrotherapeutic Apparatus
Streamex Corp.
STEX · Security & Commodity Brokers, Dealers, Exchanges & Services
CONMED Corp
CNMD · Electromedical & Electrotherapeutic Apparatus
CONMED Corp is a U.S.-based medical technology company focused on devices and equipment used in surgical procedures.
Last updated: 28/04/2026